Lipid Metabolism Practice Questions

Q: How does insulin affect lipid metabolism?

Inhibits lipolysis. ***Inhibits lipolysis*** - Insulin **downregulates hormone-sensitive lipase (HSL)** activity, a key enzyme responsible for breaking down stored triglycerides into fatty acids and glycerol. - By inhibiting lipolysis, insulin promotes the storage of energy and prevents the release of fatty acids into circulation. *Stimulates ketogenesis in adipose tissue* - Ketogenesis primarily occurs in the **liver** during periods of low insulin and high glucagon, not typically in adipose tissue. - Insulin's primary role is to **reduce** ketone body production by promoting glucose utilization and fatty acid storage. *Increases fatty acid oxidation* - Insulin **reduces fatty acid oxidation** (beta-oxidation) by stimulating malonyl-CoA production, which inhibits carnitine palmitoyltransferase 1 (CPT1), preventing fatty acid entry into mitochondria. - Its main effect is to promote **fatty acid synthesis and storage**, not their breakdown for energy. *Activates hormone-sensitive lipase (HSL)* - Insulin has an **inhibitory effect on HSL** through dephosphorylation, while glucagon and catecholamines activate HSL. - The activation of HSL would lead to the **breakdown of triglycerides**, which is contrary to insulin's role in promoting energy storage.

Q: Which lysosomal enzyme deficiency is associated with a disease characterized by the accumulation of glucocerebrosides in cells?

Glucocerebrosidase deficiency. **Correct: Glucocerebrosidase deficiency** - This deficiency leads to **Gaucher disease**, specifically characterized by the accumulation of **glucocerebrosides** in macrophages within the lysosome. - The accumulated glucocerebrosides impede normal cellular function, particularly in the **spleen, liver, bone marrow**, and sometimes the nervous system. *Incorrect: Alpha-galactosidase deficiency* - This deficiency causes **Fabry disease**, leading to the accumulation of **globotriaosylceramide (Gb3)**, primarily affecting the kidneys, heart, and nervous system. - Clinical features include **neuropathic pain**, angiokeratomas, and renal failure, which are distinct from the symptoms of glucocerebroside accumulation. *Incorrect: Hexosaminidase A deficiency* - This enzyme deficiency is responsible for **Tay-Sachs disease**, marked by the accumulation of **GM2 gangliosides**, predominantly in neuronal lysosomes. - It results in rapidly progressive neurodegeneration, **developmental regression**, and a characteristic **cherry-red spot** on the retina. *Incorrect: Sphingomyelinase deficiency* - This deficiency is associated with **Niemann-Pick disease**, types A and B, causing the accumulation of **sphingomyelin** in various tissues. - Niemann-Pick disease typically presents with hepatosplenomegaly, **neurodegeneration** (Type A), and often has foam cells.

Q: In a patient with CPT I deficiency, what best describes the primary consequence on fatty acid metabolism?

Inhibits FA transport to mitochondria. ***Inhibits FA transport to mitochondria*** - **CPT I (Carnitine Palmitoyltransferase I)** is the rate-limiting enzyme in the **carnitine shuttle system**, which is essential for transporting long-chain fatty acids into the mitochondrial matrix for **beta-oxidation**. - A deficiency in CPT I directly prevents the formation of **acylcarnitine**, thereby blocking the entry of fatty acids into the mitochondria for energy production. *Enhances FA synthesis* - Fatty acid synthesis and fatty acid oxidation are distinct metabolic pathways that are generally regulated inversely. - A CPT I deficiency would lead to an accumulation of fatty acids in the cytoplasm, which might *downregulate* synthesis through feedback mechanisms, rather than enhance it. *Increases ketogenesis* - Ketogenesis is the process of producing ketone bodies from fatty acids in the liver, primarily when glucose is scarce. - Since CPT I deficiency impairs the transport of fatty acids into the mitochondria, it would *decrease* the availability of substrates for beta-oxidation, thus reducing ketogenesis. *Reduces lipolysis* - Lipolysis is the breakdown of stored triglycerides into free fatty acids and glycerol, primarily occurring in adipose tissue. - CPT I deficiency affects the *utilization* of fatty acids, not their release from storage, so it would not directly reduce lipolysis.

Q: A patient with high levels of LDL and normal levels of HDL and triglycerides is likely suffering from which type of familial dyslipidemia?

Familial hypercholesterolemia. ***Familial hypercholesterolemia*** - This condition is characterized by significantly **elevated LDL-C levels** due to defects in the LDL receptor pathway, leading to impaired clearance of LDL from the blood. - **HDL and triglyceride levels typically remain normal**, which aligns perfectly with the patient's lipid profile. *Familial combined hyperlipidemia* - This disorder involves **elevated levels of both cholesterol (primarily LDL-C) and triglycerides**, often with low HDL-C levels. - The patient's **normal triglyceride levels** make this diagnosis less likely. *Dysbetalipoproteinemia* - This condition is characterized by increased levels of **chylomicron remnants** and **VLDL remnants (IDL)**, leading to elevated cholesterol and triglycerides. - It typically results in **elevated triglycerides and cholesterol**, which is not seen here as triglycerides are normal. *Familial hypertriglyceridemia* - This condition primarily involves **markedly elevated triglyceride levels**, often with normal or only slightly elevated cholesterol and characteristically low HDL-C levels. - The patient's **normal triglyceride levels** directly rule out this diagnosis.

Q: Which of the following enzymes is inhibited by malonyl-CoA to prevent simultaneous fatty acid synthesis and degradation?

Carnitine palmitoyltransferase I. ***Carnitine palmitoyltransferase I*** - **Malonyl-CoA** inhibits **carnitine palmitoyltransferase I (CPT1)**, which is crucial for transporting fatty acyl-CoAs into the mitochondria for **beta-oxidation**. - This inhibition ensures that when fatty acid synthesis is active (producing malonyl-CoA), fatty acid degradation is simultaneously suppressed, preventing a futile cycle. *Acetyl-CoA carboxylase* - **Acetyl-CoA carboxylase (ACC)** is the enzyme responsible for synthesizing **malonyl-CoA** from acetyl-CoA, not inhibited by it. - ACC is the committed step in **fatty acid synthesis** and is subject to allosteric regulation by citrate (activator) and long-chain fatty acids (inhibitor). *HMG-CoA reductase* - **HMG-CoA reductase** is a key enzyme in the synthesis of **cholesterol**, not directly involved in the primary regulation of fatty acid synthesis and degradation by malonyl-CoA. - It is inhibited by cholesterol and statin drugs. *Fatty acid synthase* - **Fatty acid synthase** is a multi-enzyme complex responsible for the elongation of fatty acids using **malonyl-CoA** as a substrate. - It is activated, not inhibited, by malonyl-CoA, which serves as a building block for fatty acid chains.

Q: What is the primary cause of ketoacidosis in uncontrolled diabetes mellitus?

Fat metabolism producing ketone bodies. ***Fat metabolism producing ketone bodies*** - In uncontrolled diabetes, the body cannot use **glucose** for energy due to insulin deficiency or resistance, leading to excessive breakdown of **fats** (lipolysis) for energy. - Free fatty acids undergo **β-oxidation** in the liver, producing excess acetyl-CoA that enters the **ketogenesis pathway**. - This produces large amounts of **ketone bodies** (acetoacetate, β-hydroxybutyrate, and acetone), which are acidic and accumulate faster than peripheral tissues can utilize them. - The accumulation of these organic acids lowers blood pH, causing **metabolic ketoacidosis** - the hallmark of diabetic ketoacidosis (DKA). *High blood glucose levels* - While hyperglycemia is characteristic of uncontrolled diabetes, it is a **consequence** of the underlying metabolic derangement, not the direct cause of the acidosis. - Hyperglycemia contributes to osmotic diuresis, dehydration, and electrolyte imbalances, but the **acidosis component is specifically due to ketone accumulation**. *Excessive insulin production* - **Diabetic ketoacidosis (DKA)** is characterized by an **absolute or relative deficiency of insulin**, not excessive production. - High insulin levels would promote glucose uptake into cells and inhibit lipolysis, preventing fat breakdown and thus preventing ketone body formation. *Lack of glucagon* - Glucagon levels are typically **elevated** in uncontrolled diabetes, as the body perceives a state of cellular starvation despite high blood glucose. - **Glucagon promotes glycogenolysis, gluconeogenesis, and lipolysis**, contributing to both hyperglycemia and enhanced ketone body formation, not preventing it.

Q: A patient with hypercholesterolemia has low LDL receptor activity. Which gene mutation is most likely responsible?

LDLR. ***LDLR*** - Mutations in the **LDLR (low-density lipoprotein receptor) gene** directly lead to reduced or dysfunctional LDL receptors, preventing efficient clearance of LDL from the blood. - This is the **most common genetic cause** of **Familial Hypercholesterolemia (FH)**, accounting for **~85-90% of cases**, characterized by very high LDL-C levels and premature cardiovascular disease. - **Most likely answer** when low LDL receptor activity is described. *APOB* - Mutations in the **APOB gene (apolipoprotein B)** can affect the binding of LDL to its receptor through **defective apolipoprotein B-100**, which is the ligand for the LDL receptor. - This causes a rare form of FH (~5-10% of cases) but represents a **ligand defect** rather than a primary **receptor defect**. - The receptor itself has normal structure but cannot bind LDL effectively. *PCSK9* - **PCSK9 (proprotein convertase subtilisin/kexin type 9)** regulates LDL receptor degradation, and **gain-of-function mutations** lead to **increased degradation of LDL receptors**, resulting in **reduced LDL receptor numbers and activity** on cell surfaces. - This does cause hypercholesterolemia and low functional LDL receptor activity, but accounts for only **~1-3% of FH cases**, making it **much less likely** than LDLR mutations. - Loss-of-function PCSK9 mutations conversely lead to **increased LDL receptors** and lower LDL levels (protective). *APOE* - **APOE (apolipoprotein E)** plays a crucial role in the metabolism of **chylomicron and VLDL remnants**, primarily binding to hepatic receptors for remnant clearance. - While APOE polymorphisms (E2, E3, E4) influence lipid levels and cardiovascular risk, they do not directly cause **reduced LDL receptor activity** or classic familial hypercholesterolemia. - APOE2 homozygosity can cause **Type III hyperlipoproteinemia** (dysbetalipoproteinemia), not the LDL receptor defect described.

Q: Which enzyme is responsible for converting dihydroxyacetone phosphate to glycerol-3-phosphate during triglyceride synthesis?

Glycerol-3-phosphate dehydrogenase. ***Glycerol-3-phosphate dehydrogenase*** - This enzyme **catalyzes the reduction** of **dihydroxyacetone phosphate (DHAP)**, a glycolysis intermediate, to **glycerol-3-phosphate**. - **NADH** serves as the **reducing agent** in this reaction, converting DHAP to glycerol-3-phosphate, which is the backbone for triglyceride synthesis. *Glycerol kinase* - This enzyme catalyzes the phosphorylation of **free glycerol** to **glycerol-3-phosphate**, using **ATP**. - It is primarily active in the **liver** and kidney, as adipocytes lack this enzyme, meaning they cannot directly use free glycerol for triglyceride synthesis. *Acyl-CoA synthetase* - This enzyme is responsible for **activating fatty acids** by converting them into **acyl-CoA**, using **ATP** and **CoA**. - This activation step is essential before fatty acids can be incorporated into triglycerides or phospholipids. *Phosphatidate phosphatase* - This enzyme **removes a phosphate group** from **phosphatidic acid** to form **diacylglycerol (DAG)**. - DAG is then acylated to form triglycerides, making this enzyme crucial in the final steps of triglyceride synthesis.

Q: What is the role of lecithin-cholesterol acyltransferase (LCAT) in lipid metabolism?

Converts free cholesterol into cholesteryl esters. ***Converts free cholesterol into cholesteryl esters*** - **LCAT** is an enzyme synthesized in the liver and secreted into the bloodstream, where it associates with **HDL** particles. - Its primary role is to catalyze the esterification of **free cholesterol** in the surface of lipoproteins, especially HDL, into **cholesteryl esters** using a fatty acid from lecithin. This traps cholesterol within the lipoprotein core, facilitating cholesterol transport. *Hydrolyzes triglycerides in lipoproteins* - The hydrolysis of triglycerides in lipoproteins, particularly **chylomicrons** and **VLDLs**, is primarily carried out by **lipoprotein lipase (LPL)**, an enzyme found on the endothelial surface of capillaries. - **Hepatic lipase (HL)** also contributes to triglyceride hydrolysis, especially in remnants and HDL, but LCAT's role is specifically cholesterol esterification. *Synthesizes triglycerides in the liver* - The synthesis of triglycerides in the liver, a process known as **lipogenesis**, involves enzymes such as **glycerol-3-phosphate acyltransferase** and **diacylglycerol acyltransferase (DGAT)**. - These enzymes are involved in assembling fatty acids and glycerol-3-phosphate into triglycerides, which are then packaged into **VLDL** particles for transport. *Breaks down cholesterol into bile acids* - The breakdown of cholesterol into **bile acids** (bile acid synthesis) occurs in the liver and is a major pathway for cholesterol elimination. - The rate-limiting enzyme in this process is **cholesterol 7-alpha-hydroxylase**, which initiates the conversion of cholesterol into primary bile acids.

Question 1

How does insulin affect lipid metabolism?

Accepted Answer

Inhibits lipolysis

Answer

Stimulates ketogenesis in adipose tissue

Answer

Increases fatty acid oxidation

Answer

Activates hormone-sensitive lipase (HSL)

Question 2

Which lysosomal enzyme deficiency is associated with a disease characterized by the accumulation of glucocerebrosides in cells?

Accepted Answer

Glucocerebrosidase deficiency

Answer

Alpha-galactosidase deficiency

Answer

Hexosaminidase A deficiency

Answer

Sphingomyelinase deficiency

Question 3

A patient with muscle weakness and hypoketotic hypoglycemia is diagnosed with CPT II deficiency. How does this deficiency affect fatty acid metabolism?

Accepted Answer

Inhibits FA transport into mitochondria; reduced β-oxidation

Answer

Enhances FA synthesis; lipid accumulation

Answer

Increases ketogenesis; ketoacidosis

Answer

Reduces lipolysis; decreased free FAs

Question 4

In a patient with CPT I deficiency, what best describes the primary consequence on fatty acid metabolism?

Accepted Answer

Inhibits FA transport to mitochondria

Answer

Enhances FA synthesis

Answer

Increases ketogenesis

Answer

Reduces lipolysis

Question 5

A patient with high levels of LDL and normal levels of HDL and triglycerides is likely suffering from which type of familial dyslipidemia?

Accepted Answer

Familial hypercholesterolemia

Answer

Familial combined hyperlipidemia

Answer

Dysbetalipoproteinemia

Answer

Familial hypertriglyceridemia

Question 6

Which of the following enzymes is inhibited by malonyl-CoA to prevent simultaneous fatty acid synthesis and degradation?

Accepted Answer

Carnitine palmitoyltransferase I

Answer

Acetyl-CoA carboxylase

Answer

HMG-CoA reductase

Answer

Fatty acid synthase

Question 7

What is the primary cause of ketoacidosis in uncontrolled diabetes mellitus?

Accepted Answer

Fat metabolism producing ketone bodies

Answer

High blood glucose levels

Answer

Excessive insulin production

Answer

Lack of glucagon

Question 8

A patient with hypercholesterolemia has low LDL receptor activity. Which gene mutation is most likely responsible?

Accepted Answer

LDLR

Answer

APOB

Answer

PCSK9

Answer

APOE

Question 9

Which enzyme is responsible for converting dihydroxyacetone phosphate to glycerol-3-phosphate during triglyceride synthesis?

Accepted Answer

Glycerol-3-phosphate dehydrogenase

Answer

Glycerol kinase

Answer

Acyl-CoA synthetase

Answer

Phosphatidate phosphatase

Question 10

What is the role of lecithin-cholesterol acyltransferase (LCAT) in lipid metabolism?

Accepted Answer

Converts free cholesterol into cholesteryl esters

Answer

Hydrolyzes triglycerides in lipoproteins

Answer

Synthesizes triglycerides in the liver

Answer

Breaks down cholesterol into bile acids

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?